Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing CollaborationBusiness Wire • 12/18/23
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug ScreeningBusiness Wire • 12/12/23
Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/08/23
Charles River® and S&P Global Market Intelligence Announce Collaboration to Streamline Primary Issuance in Charles River® IMSBusiness Wire • 11/28/23
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing CollaborationBusiness Wire • 11/28/23
Charles River Laboratories: Mr. Market Went From Overvaluation To UndervaluationSeeking Alpha • 11/26/23
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular ProductsBusiness Wire • 11/16/23
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and OncologyPRNewsWire • 11/13/23
Charles River Laboratories' Industry Experts to Present Advanced Modalities at Neuroscience 2023Business Wire • 11/09/23
Charles River Laboratories International, Inc. (CRL) Q3 2023 Earnings Call TranscriptSeeking Alpha • 11/08/23
Charles River (CRL) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/08/23
Unlocking Q3 Potential of Charles River (CRL): Exploring Wall Street Estimates for Key MetricsZacks Investment Research • 11/06/23
Consulting firm Charles River raises dividend to boost yield above the S&P 500's, while profit and revenue miss expectationsMarket Watch • 11/02/23
Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to DeclineZacks Investment Research • 11/01/23